Pharmaceutical Technology on MSN
Health Canada approves Santhera’s Agamree to treat DMD
Health Canada has approved Santhera Pharmaceuticals’ Agamree (vamorolone) drug for treating Duchenne muscular dystrophy (DMD) ...
Duchenne muscular dystrophy, or DMD, is an X-linked progressive and severe neuromuscular disease caused by the lack of functional dystrophin, which causes atrophy and weakness in skeletal and heart ...
10don MSN
Dyne’s Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data
Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best stocks to buy under $20. On September 29, Dyne Therapeutics announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback